EA022788B1 - Новые терапевтические и диагностические средства - Google Patents

Новые терапевтические и диагностические средства Download PDF

Info

Publication number
EA022788B1
EA022788B1 EA201270124A EA201270124A EA022788B1 EA 022788 B1 EA022788 B1 EA 022788B1 EA 201270124 A EA201270124 A EA 201270124A EA 201270124 A EA201270124 A EA 201270124A EA 022788 B1 EA022788 B1 EA 022788B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
peptide
combination
peptides
domain
Prior art date
Application number
EA201270124A
Other languages
English (en)
Russian (ru)
Other versions
EA201270124A1 (ru
Inventor
Мая Соммерфельт Гренвольд
Ангус Далглейш
Эйнар Теннес Ланге
Йенс Олоф Хольмберг
Пер Бенгтссон
Биргер Серенсен
Original Assignee
Бионор Иммуно Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионор Иммуно Ас filed Critical Бионор Иммуно Ас
Publication of EA201270124A1 publication Critical patent/EA201270124A1/ru
Publication of EA022788B1 publication Critical patent/EA022788B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201270124A 2009-07-03 2010-07-03 Новые терапевтические и диагностические средства EA022788B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09164565 2009-07-03
US22343609P 2009-07-07 2009-07-07
PCT/EP2010/059513 WO2011000962A2 (en) 2009-07-03 2010-07-03 Novel therapeutic and diagnostic means

Publications (2)

Publication Number Publication Date
EA201270124A1 EA201270124A1 (ru) 2012-07-30
EA022788B1 true EA022788B1 (ru) 2016-03-31

Family

ID=42752402

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270124A EA022788B1 (ru) 2009-07-03 2010-07-03 Новые терапевтические и диагностические средства

Country Status (10)

Country Link
US (2) US9200065B2 (enExample)
EP (1) EP2448593B1 (enExample)
JP (1) JP5946766B2 (enExample)
CN (1) CN102711791A (enExample)
BR (1) BR112012000032A2 (enExample)
CA (1) CA2767063A1 (enExample)
EA (1) EA022788B1 (enExample)
NZ (1) NZ597458A (enExample)
WO (1) WO2011000962A2 (enExample)
ZA (1) ZA201200370B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2642258C1 (ru) * 2016-12-27 2018-01-24 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Рекомбинантный химерный полипептид-иммуноген nTBI, обладающий способностью индуцировать антитела, нейтрализующие вирус иммунодефицита человека 1 типа, и предназначенный для использования в качестве компонента вакцины против ВИЧ-1

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767063A1 (en) 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means
JP6294076B2 (ja) * 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
FR2987836A1 (fr) * 2012-03-09 2013-09-13 Biomerieux Sa Peptides d'interference et procede de detection de microorganismes
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
WO2013182661A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
EP3099322A1 (en) * 2014-01-27 2016-12-07 Bionor Immuno AS Method for the vaccination against hiv
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
AU2016249404B2 (en) * 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN106282214A (zh) * 2016-08-03 2017-01-04 康众（北京）生物科技有限公司 一种快速获得纳米抗体的方法及其应用
CN108593601A (zh) * 2018-04-11 2018-09-28 珠海国际旅行卫生保健中心 一种快速检测HIV-1的SPRi生物芯片制备方法及其应用
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
CN113143974B (zh) * 2021-03-03 2023-06-06 武汉科技大学 一种hiv感染致神经损伤动物模型的建立方法及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5298419A (en) * 1988-03-31 1994-03-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
HUT62316A (en) * 1990-09-25 1993-04-28 Hiver Ltd Process for producing aids vaccine and for diagnosing aids
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5697151A (en) 1995-08-07 1997-12-16 General Electric Company Method for repairing partitions of a turbine diaphragm
ATE359831T1 (de) 1997-01-22 2007-05-15 Zycos Inc Mikropartikel zur verabreichung von nukleinsaeuren
CN1195702A (zh) * 1997-04-08 1998-10-14 军事医学科学院基础医学研究所 Hiv－1多表位重组膜抗原及其表达
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
US6911527B1 (en) 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US20110033522A1 (en) * 2007-09-26 2011-02-10 Dana-Farber Cancer Institute, Inc. Reagents for inducing an immune response
US20090203884A1 (en) 2008-01-31 2009-08-13 Healthbanks Biotech Co., Ltd. Chimeric hiv fusion proteins as vaccines
CA2767063A1 (en) 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2642258C1 (ru) * 2016-12-27 2018-01-24 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Рекомбинантный химерный полипептид-иммуноген nTBI, обладающий способностью индуцировать антитела, нейтрализующие вирус иммунодефицита человека 1 типа, и предназначенный для использования в качестве компонента вакцины против ВИЧ-1

Also Published As

Publication number Publication date
US9200065B2 (en) 2015-12-01
AU2010267996A1 (en) 2012-02-02
NZ597458A (en) 2014-01-31
WO2011000962A3 (en) 2011-03-31
EA201270124A1 (ru) 2012-07-30
US10251949B2 (en) 2019-04-09
CA2767063A1 (en) 2011-01-06
WO2011000962A9 (en) 2011-08-18
EP2448593A2 (en) 2012-05-09
JP2012531219A (ja) 2012-12-10
WO2011000962A2 (en) 2011-01-06
EP2448593B1 (en) 2020-11-25
CN102711791A (zh) 2012-10-03
ZA201200370B (en) 2019-07-31
BR112012000032A2 (pt) 2016-03-15
US20120263720A1 (en) 2012-10-18
JP5946766B2 (ja) 2016-07-06
US20160144019A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
JP5946766B2 (ja) Ｈｉｖワクチン組成物における使用又は診断手段としての使用のためのｈｉｖ関連ペプチドの組合せ又は融合物
CN103483447B (zh) 抗hpv l1蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途
US9266928B2 (en) Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction
US20130164289A1 (en) Human cytomegalovirus vaccine
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
JP2001509368A (ja) Ｈｉｖの増殖を抑える方法及び組成物
JP5187883B2 (ja) 抗原ペプチドおよびその利用
KR20190056382A (ko) 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
KR20130041185A (ko) 디자이너(designer) 펩티드-기반 pcv2 백신
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
US20250109175A1 (en) Recombinant gp120 protein with v1-loop deletion
CN101591379A (zh) 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
Yu et al. Fine mapping and conservation analysis of linear B-cell epitopes of peste des petits ruminants virus hemagglutinin protein
CN105085672B (zh) 3d蛋白特异性单克隆免疫球蛋白a抗体及其组合物
CN105085671B (zh) 抗肠道病毒3d蛋白的单克隆免疫球蛋白g抗体及其免疫原性组合物
US20250059238A1 (en) Recombinant hiv env polypeptides and their uses
KR20220040423A (ko) 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
CN100497377C (zh) Sars冠状病毒结构蛋白orf3及其应用
JP2003515340A (ja) マイコプラズマ・ミコイデス亜種ミコイデスＳＣの抗原性タンパク質ＬｐｐＱ、その調製および使用
US20240092840A1 (en) Vaccine formulation comprising recombinant overlapping peptides and native proteins
AU2010267996B2 (en) HIV related peptides combination or fusion for use in HIV vaccine composition or as diagnostic means
Dai et al. Application and identification of monoclonal antibody targeting a novel epitope on p72 protein of African swine fever virus
US20210008193A1 (en) Protein antigens for vaccinating against nontypeable haemophilus influenzae
HK1174855A (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
WO2025104741A1 (en) A universal influenza vaccine candidate and its uses thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU